These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 11265642)
1. Optimizing therapeutic strategies to inhibit circulating soluble target molecules with monoclonal antibodies: example of the soluble IL-6 receptors. Brochier J; Liautard J; Jacquet C; Gaillard JP; Klein B Eur J Immunol; 2001 Jan; 31(1):259-64. PubMed ID: 11265642 [TBL] [Abstract][Full Text] [Related]
2. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma. Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391 [TBL] [Abstract][Full Text] [Related]
3. Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies. Liautard J; Gaillard JP; Mani JC; Montero-Julian F; Duperray C; Lu ZY; Jourdan M; Klein B; Brailly H; Brochier J Eur Cytokine Netw; 1994; 5(3):293-300. PubMed ID: 7524715 [TBL] [Abstract][Full Text] [Related]
4. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model. Pallua N; Low JF; von Heimburg D Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624 [TBL] [Abstract][Full Text] [Related]
5. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. Finkelman FD; Madden KB; Morris SC; Holmes JM; Boiani N; Katona IM; Maliszewski CR J Immunol; 1993 Aug; 151(3):1235-44. PubMed ID: 8393043 [TBL] [Abstract][Full Text] [Related]
6. Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells. Finotto S; Eigenbrod T; Karwot R; Boross I; Doganci A; Ito H; Nishimoto N; Yoshizaki K; Kishimoto T; Rose-John S; Galle PR; Neurath MF Int Immunol; 2007 Jun; 19(6):685-93. PubMed ID: 17496315 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-32 monoclonal antibodies for immunohistochemistry, Western blotting, and ELISA. Kim KH; Shim JH; Seo EH; Cho MC; Kang JW; Kim SH; Yu DY; Song EY; Lee HG; Sohn JH; Kim J; Dinarello CA; Yoon DY J Immunol Methods; 2008 Apr; 333(1-2):38-50. PubMed ID: 18252253 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma. Tsunenari T; Akamatsu K; Kaiho S; Sato K; Tsuchiya M; Koishihara Y; Kishimoto T; Ohsugi Y Anticancer Res; 1996; 16(5A):2537-44. PubMed ID: 8917348 [TBL] [Abstract][Full Text] [Related]
9. Soluble cytokine receptors in renal vasculitis and lupus nephritis. Tesar V; Jirsa M; Zima T; Kalousová M; Bartunková J; Stejskalová A; Dostál C; Zabka J Med Sci Monit; 2002 Jan; 8(1):BR24-9. PubMed ID: 11782670 [TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481 [TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-6 receptor alpha inhibits the cytokine-Induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture. Matsumiya T; Imaizumi T; Fujimoto K; Cui X; Shibata T; Tamo W; Kumagai M; Tanji K; Yoshida H; Kimura H; Satoh K Exp Cell Res; 2001 Sep; 269(1):35-41. PubMed ID: 11525637 [TBL] [Abstract][Full Text] [Related]
14. Profile of soluble cytokine receptors in Crohn's disease. Gustot T; Lemmers A; Louis E; Nicaise C; Quertinmont E; Belaiche J; Roland S; Van Gossum A; Devière J; Franchimont D Gut; 2005 Apr; 54(4):488-95. PubMed ID: 15753533 [TBL] [Abstract][Full Text] [Related]
15. Role of interleukin-15 and interleukin-18 in the secretion of sIL-6R and sgp130 by human neutrophils. Jablonska E; Marcinczyk M Mediators Inflamm; 2003 Jun; 12(3):179-83. PubMed ID: 12857602 [TBL] [Abstract][Full Text] [Related]
16. [Effect of IL-6/sIL-6R on ex vivo expansion of human cord blood derived CD34+ cells]. Feng JF; Zhuang M; Zhu LJ; Sheng ZL; Zhu YQ; Li CP Ai Zheng; 2004 Jun; 23(6):715-8. PubMed ID: 15191679 [TBL] [Abstract][Full Text] [Related]
17. Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice. Mihara M; Koishihara Y; Fukui H; Yasukawa K; Ohsugi Y Immunology; 1991 Sep; 74(1):55-9. PubMed ID: 1718855 [TBL] [Abstract][Full Text] [Related]
18. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Lauta VM Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143 [TBL] [Abstract][Full Text] [Related]
19. A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells. Huang YW; Vitetta ES Hybridoma; 1993 Oct; 12(5):621-30. PubMed ID: 8300137 [TBL] [Abstract][Full Text] [Related]
20. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Iwanami K; Matsumoto I; Tanaka-Watanabe Y; Inoue A; Mihara M; Ohsugi Y; Mamura M; Goto D; Ito S; Tsutsumi A; Kishimoto T; Sumida T Arthritis Rheum; 2008 Mar; 58(3):754-63. PubMed ID: 18311788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]